autologous adipose-derived mesenchymal stromal cells (Mayo Clinic)

This investigational autologous cell therapy, developed by the Mayo Clinic, utilizes adipose-derived mesenchymal stromal cells (AMSCs) to prevent biliary complications in patients undergoing living donor liver transplantation (LDLT). The cells are harvested from the patient's own fat tissue, processed, and then applied directly to the biliary anastomosis site during the transplant surgery. The therapy leverages the innate immunosuppressive, angiogenic, and tissue-remodeling properties of mesenchymal stromal cells to enhance healing, reduce fibrosis, and promote neoangiogenesis, thereby aiming to prevent common post-transplant issues such as biliary strictures and leaks.

Other names

autologous adipose-derived mesenchymal stem cellsautologous AMSCAMSC